CDR2 genes were upregulated in all the fluconazole-resistant C. albicans isolates, whereas only a few isolates showed high expression of MDR1, FLU1 and ERG11 genes compared with the control strain. In conclusion, overexpression of the CDR1 and CDR2 genes may play an important role in fluconazole-resistant C. albicans with G487T and T916C mutations.
Introduction
Fungi in the genus Candida (especially Candida albicans) are the most common cause of opportunistic mycoses. C. albicans is a ubiquitous human pathogen that can lead to serious diseases in immunocompromised patients such as those with cancer, transplants or human immunodeficiency virus (HIV) infection. 1 Historically, azole drugs have been widely used as the first-line treatment for many different fungal infections; in particular, the azole derivative fluconazole is commonly used to treat candidiasis. Resistant strains often emerge during prolonged administration of broadspectrum antifungal agents or after prophylactic treatment. 2 There are at least four common explanations for the mechanism of azole resistance in C. albicans. The first is the alteration of the drug target enzyme. One such example is a point mutation in the 14αdemethylase (ERG11) gene that can affect the affinity between azole drugs and the target enzyme. 3 Indeed, the presence of some mutations has been shown to correlate with azole resistance, and two mutations that can contribute to an increase in the effective minimum inhibitory concentration (MIC) of azole drugs when they coexist in the same strain have been described. 4 A second possible mechanism for drug resistance is overexpression of the Candida drug resistance (CDR)1 and CDR2 genes, which encode transporters of the ATP-binding cassette (ABC) family, and the multidrug resistance (MDR)1 gene, which codes for a major facilitator transporter. Recently it has been found that the resistant to 7aminocholesterol (RTA2) gene may also be involved in the development of azole resistance in a mutant C. albicans strain with deletions of CDR1, CDR2 and MDR1. 5 Another major facilitator gene, fluconazole resistance (FLU)1, has also been identified in C. albicans. This gene has been reported to increase azole susceptibility when it is deleted, but its overexpression has not been correlated with azole resistance in C. albicans. 6 As a third mechanism, biofilms may be correlated with resistance development in C. albicans 7 and, fourthly, vesicular vacuoles from resistant isolates may act as a novel fluconazole resistance mechanism. 8 During the last two decades much research has been done to understand azole resistance; however, the mechanisms of drug resistance are complicated and have yet to be fully clarified. In a previous investigation, two mutations of ERG11 (G487T [A114S] and T916C [Y257H]) were shown to coexist in a collection of clinical C. albicans isolates. 9 To date, other wild type C. albicans strains with the same mutation have not been found in China. These two mutations occurred in 14 fluconazole-resistant strains, without any other mutations in the ERG11 gene. In order to investigate whether this particular mutation is associated with fluconazole resistance, the 14 isolates were studied using real-time reverse transcription-polymerase chain reaction (RT-PCR). The mRNA levels from these isolates were quantified in order to understand the potential molecular mechanisms of fluconazole resistance in C. albicans from non-HIV-infected patients.
Materials and methods

STRAINS
Fluconazole-resistant strains of C. albicans with the ERG11 mutations G487T (A114S) and T916C (Y257H) were obtained from non-HIV-infected patients who had undergone an examination for HIV antibody at the Second Affiliated Hospital, Sun Yat-Sen University, Guangzhou, or the Qilu Hospital of Shandong University, Jinan, China. The control C. albicans strain, ATCC 10231, was obtained from the Jiangsu Provincial Centre for Disease Prevention and Control, Nanjing, China.
After being identified by conventional methods, all the strains were cultured on modified Sabouraud dextrose agar at 4°C. Verbal informed consent was obtained from all participants from whom study samples were obtained.
FLUCONAZOLE SUSCEPTIBILITY
The in vitro susceptibilities of the C. albicans isolates to fluconazole were determined using the broth microdilution method 10 and a disc diffusion assay 11 
GENOTYPING OF STRAINS
Genomic DNA was isolated using a E.Z.N.A. ® Yeast DNA Kit (Omega Bio-Tek, Norcross, GA, USA) according to the manufacturer's instructions and as described elsewhere. 9 The genotypes were identified from the electrophoresis pattern of PCR products that span the site of the transposable intron in the 25S rDNA: 12 a single PCR product corresponds to C. albicans genotype A (450 bp) or B (840 bp) or C. dubliniensis (1080 bp), whereas the C. albicans genotype C isolate has two major products (450 bp and 840 bp).
REAL-TIME RT-PCR ANALYSIS
For each isolate, an overnight culture was propagated in fresh yeast extract peptone dextrose broth with constant shaking at 30°C until the mid-logarithmic phase was reached. Total cellular RNA was extracted using the E.Z.N.A. ® Yeast RNA Kit (Omega Bio-Tek), following the manufacturer's instructions. All RNA samples were treated with RNase-free DNase I to prevent contamination with genomic DNA. The quality of RNA was checked using a spectrophotometer (DU ® 800; Beckman Coulter Inc., Brea, CA, USA): a ratio of A 260 nm :A 280 nm of 1.8 -2.0 corresponded to 90 -100% pure nucleic acid. The cDNA for each strain was synthesized in a two-step procedure using the One Step SYBR ® PrimeScript™ RT-PCR Kit (Perfect Real Time) (Takara Bio Inc., Shiga, Japan) according to the manufacturer's instructions. All of the reagents, including cellular RNA, were added to a final volume of 20 µl at the first step. The samples were then incubated at 37°C for 60 min, 95°C for 5 min and held at 4°C in a thermocycler (T-Gradient 96; Biometra GmbH, Göttingen, Germany). The synthesized cDNA samples were stored at -20°C.
The PCR primers used to amplify and identify the C. albicans CDR1, CDR2, ERG11, FLU1 and MDR1 genes were designed by Takara Biotechnology (Dalian, China) using Primer Premier 5.0 design software. The housekeeping gene 18SrRNA was used as a control. The nucleotide sequences of the primers are given in Table 1 . All of the sequences were synthesized by Shanghai Sangon Biological Engineering Technology and Services (Shanghai, China). SYBR ® Green I, a specific DNA-binding dye, was used to detect amplification. The cycling conditions were as follows: 30 -45 cycles of denaturation for 10 s at 95°C, annealing for 5 s at 57°C for 18SrRNA, MDR1, CDR2 and ERG11, at 62°C for FLU1, and at 67°C for CDR1, and elongation for 10 s at 72°C, followed by termination in a final cooling step for 30 s at 40°C. Genomic DNA contamination was examined by replacing cDNA with RNA samples in a LightCycler ® 2.0 System (Roche Diagnostics, Mannheim, Germany). When the amplification was complete, 8 µl of the amplification products were separated using 2% agarose gel electrophoresis, visualized and photographed with an ImageMaster ® Video Documentation System (Pharmacia Biotech, Piscataway, NJ, USA) to verify further their LM Chen, YH Xu, CL Zhou et al. CDR1 and CDR2 genes in fluconazole-resistant C. albicans specificity (data not shown). The expression levels of CDR1, CDR2, ERG11, FLU1 and MDR1 were evaluated using the 2 -∆∆Ct method, 13 where Ct was the average threshold cycle number from three independent experiments. Data were presented as the fold change in gene expression normalized to the 18SrRNA gene as a control.
Results
FLUCONAZOLE SUSCEPTIBILITY AND GENOTYPING
The MIC and inhibition zone diameters for each of the isolates are given in Table 2 . All 14 isolates were confirmed to be resistant to fluconazole. The CLSI recommended that trailing of C. albicans should be noted when using the broth microdilution method as it makes the breakpoint hard to determine; however, trailing growth was not observed with any of the isolates tested. The 14 fluconazole-resistant isolates studied were all genotype A ( Table 2 ).
GENE EXPRESSION
There were no primer dimers or non-specific amplification products according to the melting curves and melting peaks of the five tested genes. A single band of PCR product with the expected length on agarose gel electrophoresis also confirmed the specificity of the PCR reactions (data not shown). The CDR1 efflux gene in the 14 fluconazoleresistant isolates was upregulated 1.6 -8.0 fold (Fig. 1A) . Likewise, a 3.7 -52 fold increase in CDR2 transcript levels was observed relative to the susceptible control strain ATCC 10231 (Fig. 1B) . Isolate J4266 had the highest CDR1 expression level (Fig.  1A) , and isolate GZ18 had the highest increase in the CDR2 transcript level compared with the susceptible control strain (Fig. 1B) . The expression of MDR1, FLU1 and ERG11 varied in the different C. albicans isolates compared with ATCC 10231 (Fig. 2) . MDR1 overexpression was observed in four isolates and isolate GZ17 had the highest Fig. 2A) . Upregulation of the ERG11 gene was observed in five isolates, the highest level (a 2.8-fold increase relative to the ATCC 10231 control strain) being observed in isolate GZ03 and the lowest level (0.4-fold relative to the ATCC 10231 control strain) being observed in GZ15 (Fig. 2B) . Six strains displayed increases in FLU1 transcript levels compared with ATCC 10231 (Fig. 2C ).
Discussion
Northern blot hybridization is a well-known and often-used method for analysis of gene expression in molecular biology. The development of new PCR methods, particularly real-time quantitative RT-PCR, offers increased sensitivity and specificity, accurate quantification and increased speed of analysis, without the need for post-PCR sample processing. These techniques have several advantages over Northern blot hybridization and are increasingly favoured by researchers. Real-time quantitative RT-PCR is a recognized method for the quantification of mRNA levels in cells, bodily fluids, tissues and other clinical samples, even for specimens with a very low mRNA 14 It has also been used for the diagnosis of fungal infections, and reports on the expression of various genes in fungi (especially clinical isolates of C. albicans) measured using this method have been published. 15, 16 The present study confirmed that real-time quantitative RT-PCR is a rapid, sensitive and reproducible assay for the quantification of the expression of resistance genes in C. albicans.
Since the 1990s, antifungal drug resistance has become a major problem in the immunocompromised population, especially in those infected with HIV. 2 It has been reported that the fluconazole-resistant ratio of C. albicans in patients with candidaemia may be > 35%. 17 Azoleresistant C. albicans isolates are commonly found in HIV-infected patients who have received long-term antifungal therapy or prophylactic treatment, whereas generally C. albicans isolates from HIV uninfected patients show higher susceptibility to azole drugs. 9, 18, 19 In studying the mechanism of azole resistance, investigations have focused on alterations in the target enzyme of azole drugs, including overexpression of and mutations in the ERG11 gene. Marichal et al. 20 reported that there were three hot spots in the amino acid sequence of the Erg11 protein that correlated to fluconazole resistance (regions 105 -165, 266 -287 and 405 -488). Podust et al. 21 divided these three hotspots into four different areas using the Mycobacterium tuberculosis cytochrome P450 14α-sterol demethylase (MTCYP51) structure. ERG11 point mutations, however, occur in a random distribution in individual fluconazole-resistant isolates. The Erg11p Y132H, T315A, S405F, G464S, R467K and I471T mutations have all been shown to be associated with azole resistance. 22 -25 Some researchers have demonstrated the structural importance of the Y118 amino acid residue in maintaining C. albicans cytochrome P450 14α-sterol demethylase P450 (CACYP51) activity and determining azole susceptibility. 26 The contributions of other mutations such as Y79C, D81G, F126L and V130I to fluconazole resistance are still uncertain.
The 14 resistant isolates tested in the present study all had two simultaneous mutations, G487T (A114S) and T916C (Y257H), and no other mutations in the ERG11 gene. This was in contrast to other reports regarding ERG11 sequence analysis. 20 -26 A114S, which is near the Erg11p substrate channel, may change the affinity between Erg11p and the azole drug. Conversely, Y257H is located in the G helix, far away from the active centre, and may play a lesser role in resistance compared with A114S. 9 The sequencing results of the present study confirmed the stable existence of the G487T and T916C mutations. In 2006, these mutations were detected in an induced fluconazole-resistant strain of C. albicans in China 27 and we subsequently found them in clinical isolates from two different cities in China. 9 It is likely that G487T and/or T916C are correlated with fluconazole resistance.
The expression level of ERG11 in C. albicans varies considerably in the presence and absence of fluconazole. Overexpression of ERG11 has been observed in several azoleresistant isolates. 28 -30 Despite this, some researchers have concluded that there is no obvious link between the expression levels of ERG11 and increased fluconazole resistance. 31 In the present study, a relative quantification method was used to investigate ERG11 expression in 14 fluconazole-resistant clinical isolates of C. albicans. Five of the C. albicans strains showed upregulation of ERG11, but the others expressed lower levels of ERG11, compared with the control isolate ATCC LM Chen, YH Xu, CL Zhou et al. CDR1 and CDR2 genes in fluconazole-resistant C. albicans 10231 . Compared with the susceptible control strain, the highest level of ERG11 expression was observed in isolate GZ03 and the lowest was observed in GZ15. Relative to the ATCC 10231 control strain, ERG11 expression in GZ15 was merely two-fifths of the control level. ERG11 overexpression in only 37% (five out of 14) of the isolates indicates a poor correlation with fluconazole resistance.
Overexpression of the CDR1, CDR2 and MDR1 genes has been related to the most frequent mechanism of fluconazole resistance. 6, 28, 29, 31, 32 Indeed, overexpression of the ABC transporter genes, CDR1 and CDR2, which encode plasma membrane proteins Cdr1p and Cdr2p, has widely been accepted as an important factor in fluconazole resistance. Holmes et al. 33 proposed that Cdr1p expression levels have greater effects on fluconazole resistance in C. albicans than Cdr2p. In the present study, CDR1 and CDR2 were upregulated in the absence of fluconazole in all 14 fluconazole-resistant isolates compared with the susceptible control strain, showing that the CDR1 and CDR2 genes are coregulated in these strains. Previous studies have reported that the CDR1 and CDR2 genes are highly expressed in only some fluconazole-resistant isolates. 34, 35 Thus, the absolute overexpression of CDR1 and CDR2 in the present study is interesting. The relationship between the CDR1 and CDR2 efflux genes and the ERG11 mutations G487T and T916C in fluconazole resistance is as yet unknown.
The MDR1 gene, which encodes the major facilitator efflux pump, was observed in some of the resistant clinical C. albicans isolates. Interestingly, high expression of MDR1 in some fluconazole-susceptible isolates has also been reported. 29, 31 MDR1 message instability may contribute to the expression or lack of expression of MDR1 observed in some isolates. It should be noted that even the pattern of expression for the Mdr1 efflux pump has been reported to be variable within a single isolate. 36 In the present collection of strains, MDR1 expression was increased in only four isolates. The other isolates all displayed decreased MDR1 expression compared with the control isolate. Thus, it appears that MDR1 overexpression during the midlogarithmic phase of growth plays a minor role in fluconazole resistance in this collection of strains.
The FLU1 gene is another major facilitator gene and is similar to MDR1. It is generally believed that the overexpression of FLU1 does not correlate with azole resistance. 6, 31 FLU1 was overexpressed relative to the control strain ATCC 10231 in six of the studied isolates in the present study. In a further two isolates, FLU1 mRNA levels were almost the same as for the control strain. Thus, there is no clear link between high expression levels of FLU1 and fluconazole resistance in the 14 C. albicans isolates studied.
In summary, the efflux genes, CDR1 and CDR2, were upregulated in all the studied C. albicans isolates with ERG11 mutations, whereas the MDR1 gene only had a minor effect on fluconazole resistance. The CDR1 and CDR2 genes are, therefore, likely to play a more important role in resistance in these isolates. To our knowledge, this is the first report of a connection between co-expression of genes and fluconazole resistance in C. albicans with G487T and T916C mutations from HIV uninfected patients in China. Only a few fluconazole-resistant C. albicans samples were collected in the present study, and studies using larger sample sizes should be conducted in China to elucidate further the possible fluconazole resistance mechanisms. Further research should also be done to
